Akiisa Omura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akiisa Omura has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Jiro Okami
Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan
7 shared publicationsTomohiro Maniwa
Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan
7 shared publicationsRyo Tanaka
Department of General Thoracic Surgery, Osaka International Cancer Institute , Osaka, Japan
5 shared publicationsTakashi Hiroshima
Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan
4 shared publicationsAkihiro Ike
Department of General Thoracic Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka 541-8567, Japan
3 shared publicationsHirokazu Watari
Department of General Thoracic Surgery, Osaka International Cancer Institute , Osaka, Japan
3 shared publications
Latest Publications
- Open Access
- 24 March 2025
- Published by Springer Nature in Surgery Today
- Vol. 55 (9) , 1269-1273
Quantification of the immunohistochemical staining of fibroblast activation protein in intrathoracic solitary fibrous tumors using QuPath
Purpose: Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms that can develop in the pleura. In the past, SFTs were considered benign, but there have been reports of SFTs being highly malignant. Fibroblast activation protein (FAP) is a serine protease, overexpressed in various cancers, which has been explored as a diagnostic and therapeutic target. We analyzed patients who underwent resection of an intrathoracic SFT, including metastatic pulmonary nodules from extrathoracic organs. Methods: The subjects of this retrospective study were seven patients with a primary SFT and two with metastatic SFTs in the lungs. After immunohistochemical staining of the resected tumors, quantification of the stained area was performed using QuPath. Results: Immunohistochemical quantification of FAP showed that it was expressed to varying degrees in the intrathoracic SFTs, with higher expression levels observed in metastatic SFTs than in primary pleural SFTs. Pathological examination confirmed the expression of FAP. Conclusion: Our results support the potential usefulness of FAP in the diagnosis of intrathoracic SFTs, including metastatic pulmonary nodules.
- 24 March 2025
- Published by Springer Nature in Surgery Today
- Vol. 55 (9) , 1269-1273
Open AccessQuantification of the immunohistochemical staining of fibroblast activation protein in intrathoracic solitary fibrous tumors using QuPath
Purpose: Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms that can develop in the pleura. In the past, SFTs were considered benign, but there have been reports of SFTs being highly malignant. Fibroblast activation protein (FAP) is a serine protease, overexpressed in various cancers, which has been explored as a diagnostic and therapeutic target. We analyzed patients who underwent resection of an intrathoracic SFT, including metastatic pulmonary nodules from extrathoracic organs. Methods: The subjects of this retrospective study were seven patients with a primary SFT and two with metastatic SFTs in the lungs. After immunohistochemical staining of the resected tumors, quantification of the stained area was performed using QuPath. Results: Immunohistochemical quantification of FAP showed that it was expressed to varying degrees in the intrathoracic SFTs, with higher expression levels observed in metastatic SFTs than in primary pleural SFTs. Pathological examination confirmed the expression of FAP. Conclusion: Our results support the potential usefulness of FAP in the diagnosis of intrathoracic SFTs, including metastatic pulmonary nodules.
- Open Access
- 8 April 2024
- Published by Springer Nature in Cureus
- Vol. 16 (4) , e57820
The Impact of Kinlessness on Survival in Patients With Advanced Non-small Cell Lung Cancer: A Single-Center Retrospective Study
Objectives Among patients with advanced non-small cell lung cancer (NSCLC), there are those who do not have a spouse, family members, or friends to support them in their cancer treatment and daily life: the kinless patients. Therefore, we designed an exploratory study of kinlessness and the prognosis of advanced NSCLC. Methods We retrospectively analyzed the prognosis of clinical factors and treatment and kinlessness in patients with advanced NSCLC with wild-type or unknown status for epidermal growth factor receptor/anaplastic lymphoma kinase (EGFR/ALK) and who visited our hospital from November 2018 to February 2023. In addition to the survival analysis by kinlessness, a multivariable analysis of survival was performed for all clinical factors. In a secondary analysis, a multivariable analysis of the choice of best supportive care (BSC) was performed for all clinical factors. Results One hundred forty-four patients are included in our cohort. There were 131 patients with kin, with a median survival of 1.34 years (95% CI of 1.01-1.79 years). There were 13 patients has no kin, with a median survival of 0.53 years (95% CI 0.23-0.76 years). The log-rank analysis showed that kinless patients had significantly shorter overall survival than patients who have kin. A Cox regression analysis showed that age, distant metastasis, performance status, and kinlessness were associated with overall survival. Secondary analysis showed that there was no statistical association between kinlessness and the choice of BSC in our cohort. Conclusions Kinless patients had shorter survival than patients who have kin in our single-center, retrospective study of patients with advanced NSCLC with wild-type or unknown status for (EGFR/ALK). Further research to evaluate the clinical impact of kinlessness in the treatment of advanced NSCLC is needed.
- 8 April 2024
- Published by Springer Nature in Cureus
- Vol. 16 (4) , e57820
Open AccessThe Impact of Kinlessness on Survival in Patients With Advanced Non-small Cell Lung Cancer: A Single-Center Retrospective Study
Objectives Among patients with advanced non-small cell lung cancer (NSCLC), there are those who do not have a spouse, family members, or friends to support them in their cancer treatment and daily life: the kinless patients. Therefore, we designed an exploratory study of kinlessness and the prognosis of advanced NSCLC. Methods We retrospectively analyzed the prognosis of clinical factors and treatment and kinlessness in patients with advanced NSCLC with wild-type or unknown status for epidermal growth factor receptor/anaplastic lymphoma kinase (EGFR/ALK) and who visited our hospital from November 2018 to February 2023. In addition to the survival analysis by kinlessness, a multivariable analysis of survival was performed for all clinical factors. In a secondary analysis, a multivariable analysis of the choice of best supportive care (BSC) was performed for all clinical factors. Results One hundred forty-four patients are included in our cohort. There were 131 patients with kin, with a median survival of 1.34 years (95% CI of 1.01-1.79 years). There were 13 patients has no kin, with a median survival of 0.53 years (95% CI 0.23-0.76 years). The log-rank analysis showed that kinless patients had significantly shorter overall survival than patients who have kin. A Cox regression analysis showed that age, distant metastasis, performance status, and kinlessness were associated with overall survival. Secondary analysis showed that there was no statistical association between kinlessness and the choice of BSC in our cohort. Conclusions Kinless patients had shorter survival than patients who have kin in our single-center, retrospective study of patients with advanced NSCLC with wild-type or unknown status for (EGFR/ALK). Further research to evaluate the clinical impact of kinlessness in the treatment of advanced NSCLC is needed.
- Open Access
- 29 February 2024
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 38 (3)
Outcomes and prognostic factors of repeat pulmonary metastasectomy
OBJECTIVES: Information on prognostic factors after repeat pulmonary metastasectomy (PM) is limited, and outcomes after a third PM are not well documented. METHODS: A single-institute retrospective study was conducted. Between 2000 and 2020, 68 patients underwent repeat PM for pulmonary metastases from various cancers. Outcomes and prognostic factors for the second PM and outcomes after the third PM were analysed. RESULTS: This study included 39 men and 29 women. The mean age at second PM was 53.2 years old. The primary tumours were soft tissue sarcoma in 24 patients, colorectal cancer in 19 and osteosarcoma in 10. The interval between the first PM procedure and detection of pulmonary metastasis after the first PM (months) was ≤12 in 37 patients and >12 in 31 patients. At the second PM, 20 patients underwent lobectomy or bilobectomy, and 48 underwent sublobar resection. Complete resection was achieved in 60 patients, and 52 patients experienced recurrence after the second PM. The 5-year relapse-free survival and overall survival rates after the second PM were 27% and 48%, respectively. Multivariable analysis revealed that the interval between the first PM and the subsequent detection of pulmonary metastasis (≤12 months) was a poor prognostic factor for both relapse-free survival and overall survival after the second PM. Seventeen patients underwent a third PM, 3 of whom achieved a 3-year disease-free survival. CONCLUSIONS: Patients with a period of >12 months between the first PM and the subsequent detection of pulmonary metastases showed favourable outcomes and are thus considered good candidates for second PM. A third PM may be beneficial for selected patients.
- 29 February 2024
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 38 (3)
Open AccessOutcomes and prognostic factors of repeat pulmonary metastasectomy
OBJECTIVES: Information on prognostic factors after repeat pulmonary metastasectomy (PM) is limited, and outcomes after a third PM are not well documented. METHODS: A single-institute retrospective study was conducted. Between 2000 and 2020, 68 patients underwent repeat PM for pulmonary metastases from various cancers. Outcomes and prognostic factors for the second PM and outcomes after the third PM were analysed. RESULTS: This study included 39 men and 29 women. The mean age at second PM was 53.2 years old. The primary tumours were soft tissue sarcoma in 24 patients, colorectal cancer in 19 and osteosarcoma in 10. The interval between the first PM procedure and detection of pulmonary metastasis after the first PM (months) was ≤12 in 37 patients and >12 in 31 patients. At the second PM, 20 patients underwent lobectomy or bilobectomy, and 48 underwent sublobar resection. Complete resection was achieved in 60 patients, and 52 patients experienced recurrence after the second PM. The 5-year relapse-free survival and overall survival rates after the second PM were 27% and 48%, respectively. Multivariable analysis revealed that the interval between the first PM and the subsequent detection of pulmonary metastasis (≤12 months) was a poor prognostic factor for both relapse-free survival and overall survival after the second PM. Seventeen patients underwent a third PM, 3 of whom achieved a 3-year disease-free survival. CONCLUSIONS: Patients with a period of >12 months between the first PM and the subsequent detection of pulmonary metastases showed favourable outcomes and are thus considered good candidates for second PM. A third PM may be beneficial for selected patients.
- 8 December 2023
- Published by Wiley in World Journal of Surgery
- Vol. 48 (1) , 217-227
Development of a multivariable prediction model for prolonged air leak after lung resection
Objectives: Prolonged air leak (PAL) is a common complication of lung resection. Research on predictors of PAL using a digital drainage system (DDS) remains insufficient. In this study, we investigated the predictive factors of PAL to establish a novel early postoperative prediction model for PAL.Methods: A retrospective cohort study and validation study were conducted. We examined patients who underwent lung resection with DDS at our institute. The relationship between the clinical factors and measurements of the DDS, including the difference between the set and measured intrapleural pressure (named: additional negative pressure [ANP]) at postoperative hour (POH) 3, with PAL was analyzed.Results: A total of 494 patients were enrolled, 29 of whom had PAL. Percent forced expiratory volume in 1 s n = 133) revealed that this scoring system showed a sufficient ability to predict PAL.Conclusions: ANP at POH 3 is an independent predictor of PAL. Thus, the risk‐scoring system proposed in this study is useful for predicting PAL in the early postoperative period.
- 8 December 2023
- Published by Wiley in World Journal of Surgery
- Vol. 48 (1) , 217-227
Development of a multivariable prediction model for prolonged air leak after lung resection
Objectives: Prolonged air leak (PAL) is a common complication of lung resection. Research on predictors of PAL using a digital drainage system (DDS) remains insufficient. In this study, we investigated the predictive factors of PAL to establish a novel early postoperative prediction model for PAL.Methods: A retrospective cohort study and validation study were conducted. We examined patients who underwent lung resection with DDS at our institute. The relationship between the clinical factors and measurements of the DDS, including the difference between the set and measured intrapleural pressure (named: additional negative pressure [ANP]) at postoperative hour (POH) 3, with PAL was analyzed.Results: A total of 494 patients were enrolled, 29 of whom had PAL. Percent forced expiratory volume in 1 s n = 133) revealed that this scoring system showed a sufficient ability to predict PAL.Conclusions: ANP at POH 3 is an independent predictor of PAL. Thus, the risk‐scoring system proposed in this study is useful for predicting PAL in the early postoperative period.
- Open Access
- 10 December 2022
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 1 (2) , 231-234
Localized Synchronous Pulmonary Langerhans Cell Sarcoma and Langerhans Cell Histiocytosis
- 10 December 2022
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 1 (2) , 231-234
Open AccessLocalized Synchronous Pulmonary Langerhans Cell Sarcoma and Langerhans Cell Histiocytosis
- 6 November 2021
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 70 (3) , 273-279
Surgical indication of pulmonary metastasis arising from osteosarcoma or soft tissue sarcoma
Objectives Metastasectomy is often the local treatment for pulmonary metastases arising from osteosarcoma or soft tissue sarcoma. However, there have been few investigations on the outcomes of patients who undergo this procedure. In this study, we identified prognostic factors in patients with pulmonary metastases arising from osteosarcoma and soft tissue sarcoma to determine more appropriate eligibility criteria for metastasectomy. Methods We retrospectively examined 37 patients who underwent metastasectomy of pulmonary nodules arising from osteosarcomas or soft tissue sarcomas at our institute between 2005 and 2020. Overall and recurrence-free survival intervals were determined using univariate and multivariate analyses. Results A tumor doubling time > 1 month and a primary tumor histological type of osteosarcoma were independent predictors of longer overall survival on multivariate analysis (hazard ratios: 3.618 and 2.979, p = 0.00986 and 0.0373, respectively). Moreover, a > 1-month tumor doubling time and > 10-cm diameter of the primary tumor were independent predictors of longer recurrence-free survival (hazard ratios: 3.293 and 2.67, p = 0.0121 and 0.0134, respectively). Patients who underwent repeat pulmonary metastasectomy after complete resection of sarcoma-derived pulmonary metastases had significantly longer overall survival than those who did not (median: 5.91 years vs. 0.81 years, p < 0.0001). Conclusions Tumor doubling time is a significant predictor of clinical outcomes in patients who undergo resection of pulmonary metastases originating from sarcomas. The surgical indication for this procedure should be decided carefully, particularly for patients with metastatic lesion doubling times ≤ 1 month.
- 6 November 2021
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 70 (3) , 273-279
Surgical indication of pulmonary metastasis arising from osteosarcoma or soft tissue sarcoma
Objectives Metastasectomy is often the local treatment for pulmonary metastases arising from osteosarcoma or soft tissue sarcoma. However, there have been few investigations on the outcomes of patients who undergo this procedure. In this study, we identified prognostic factors in patients with pulmonary metastases arising from osteosarcoma and soft tissue sarcoma to determine more appropriate eligibility criteria for metastasectomy. Methods We retrospectively examined 37 patients who underwent metastasectomy of pulmonary nodules arising from osteosarcomas or soft tissue sarcomas at our institute between 2005 and 2020. Overall and recurrence-free survival intervals were determined using univariate and multivariate analyses. Results A tumor doubling time > 1 month and a primary tumor histological type of osteosarcoma were independent predictors of longer overall survival on multivariate analysis (hazard ratios: 3.618 and 2.979, p = 0.00986 and 0.0373, respectively). Moreover, a > 1-month tumor doubling time and > 10-cm diameter of the primary tumor were independent predictors of longer recurrence-free survival (hazard ratios: 3.293 and 2.67, p = 0.0121 and 0.0134, respectively). Patients who underwent repeat pulmonary metastasectomy after complete resection of sarcoma-derived pulmonary metastases had significantly longer overall survival than those who did not (median: 5.91 years vs. 0.81 years, p < 0.0001). Conclusions Tumor doubling time is a significant predictor of clinical outcomes in patients who undergo resection of pulmonary metastases originating from sarcomas. The surgical indication for this procedure should be decided carefully, particularly for patients with metastatic lesion doubling times ≤ 1 month.
- 1 July 2021
- Vol. 74 (7) , 488-491
[Dealing with Pleural Adhesion in Video-assisted Thoracoscopic Surgery].
The adhesion between the visceral and parietal pleura makes video-assisted thoracoscopic surgery (VATS) difficult or impossible. When performing VATS without conversion to thoracotomy due to pleural adhesion, it is important to( ⅰ) evaluate the presence and extent of the adhesion preoperatively, (ⅱ) carefully perform detachment, and( ⅲ) adequately repair the injured visceral pleura. We evaluate visceral sliding with the help of chest ultrasonography and plan the best approach to make utility inci-sions, camera port, and third-port incisions. Considering the difficulty in repairing the injured visceral pleura under VATS, we perform extra-pleural detachment of adhesions around the injured visceral pleura, which can facilitate the repair of the pleural injury. For repairing pleural injury, we use free mediastinal fat tissue as biological pledgets to support suturing. In this report, we present the approaches and techniques we follow to perform VATS for patients with pleural adhesion.
- 1 July 2021
- Vol. 74 (7) , 488-491
[Dealing with Pleural Adhesion in Video-assisted Thoracoscopic Surgery].
The adhesion between the visceral and parietal pleura makes video-assisted thoracoscopic surgery (VATS) difficult or impossible. When performing VATS without conversion to thoracotomy due to pleural adhesion, it is important to( ⅰ) evaluate the presence and extent of the adhesion preoperatively, (ⅱ) carefully perform detachment, and( ⅲ) adequately repair the injured visceral pleura. We evaluate visceral sliding with the help of chest ultrasonography and plan the best approach to make utility inci-sions, camera port, and third-port incisions. Considering the difficulty in repairing the injured visceral pleura under VATS, we perform extra-pleural detachment of adhesions around the injured visceral pleura, which can facilitate the repair of the pleural injury. For repairing pleural injury, we use free mediastinal fat tissue as biological pledgets to support suturing. In this report, we present the approaches and techniques we follow to perform VATS for patients with pleural adhesion.
- 29 October 2020
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 111 (5) , e361-e363
Thymic Metastasis of Ovarian Cancer 33 Years After Primary Surgery
- 29 October 2020
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 111 (5) , e361-e363
Thymic Metastasis of Ovarian Cancer 33 Years After Primary Surgery
- 1 October 2020
- Published by Elsevier in Lung Cancer
- Vol. 148, 62-68
Novel imprint cytological classification is correlated with tumor spread through air spaces in lung adenocarcinoma
- 1 October 2020
- Published by Elsevier in Lung Cancer
- Vol. 148, 62-68
Novel imprint cytological classification is correlated with tumor spread through air spaces in lung adenocarcinoma
- 29 July 2020
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 31 (3) , 305-314
Number of metastatic lymph nodes and zones as prognostic factors in non-small-cell lung cancer
OBJECTIVES: Characterizing pathological nodes (pNs) by location alone is sometimes inadequate as patients with pN1 or pN2 non-small-cell lung cancer (NSCLC) show prognostic heterogeneity. We aimed to assess the relationship of the number of metastatic lymph nodes (LNs) and zones with prognosis in NSCLC patients. METHODS: We analysed 1393 patients who underwent lobectomy with mediastinal LN dissection for NSCLC at the Osaka International Cancer Institute between January 2006 and December 2015. Patients were classified into 3 groups according to the number of LNs: n1–3, n4–6 and n7–. We investigated the relationship of prognosis with the number of metastatic LNs and metastatic zones. RESULTS: In the multivariable analyses, the number of metastatic LNs and zones were not independent factors for overall survival or recurrence-free survival in patients with pN1 disease after adjustment for age, sex, tumour histology and tumour diameter. However, n4–6 (ref. n1–3) was an independent prognostic factor for overall survival [hazard ratio (HR) 4.148, P < 0.001] in those with pN2 disease. There were no significant differences in overall survival and recurrence-free survival between pN1 (HR 0.674, P = 0.175) and pN2n1–3 disease (HR 1.056, P = 0.808). Moreover, patients with pN2 disease with a higher number of metastatic zones had a poor prognosis for recurrence-free survival [3 zones (ref. 1): HR 1.774, P = 0.051, and 4 zones (ref. 1): HR 2.173, P < 0.047]. CONCLUSIONS: The number of metastatic LNs and metastatic zones were useful prognostic factors in NSCLC patients. The findings could help in establishing a new pN classification.
- 29 July 2020
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 31 (3) , 305-314
Number of metastatic lymph nodes and zones as prognostic factors in non-small-cell lung cancer
OBJECTIVES: Characterizing pathological nodes (pNs) by location alone is sometimes inadequate as patients with pN1 or pN2 non-small-cell lung cancer (NSCLC) show prognostic heterogeneity. We aimed to assess the relationship of the number of metastatic lymph nodes (LNs) and zones with prognosis in NSCLC patients. METHODS: We analysed 1393 patients who underwent lobectomy with mediastinal LN dissection for NSCLC at the Osaka International Cancer Institute between January 2006 and December 2015. Patients were classified into 3 groups according to the number of LNs: n1–3, n4–6 and n7–. We investigated the relationship of prognosis with the number of metastatic LNs and metastatic zones. RESULTS: In the multivariable analyses, the number of metastatic LNs and zones were not independent factors for overall survival or recurrence-free survival in patients with pN1 disease after adjustment for age, sex, tumour histology and tumour diameter. However, n4–6 (ref. n1–3) was an independent prognostic factor for overall survival [hazard ratio (HR) 4.148, P < 0.001] in those with pN2 disease. There were no significant differences in overall survival and recurrence-free survival between pN1 (HR 0.674, P = 0.175) and pN2n1–3 disease (HR 1.056, P = 0.808). Moreover, patients with pN2 disease with a higher number of metastatic zones had a poor prognosis for recurrence-free survival [3 zones (ref. 1): HR 1.774, P = 0.051, and 4 zones (ref. 1): HR 2.173, P < 0.047]. CONCLUSIONS: The number of metastatic LNs and metastatic zones were useful prognostic factors in NSCLC patients. The findings could help in establishing a new pN classification.